Prakt. lékáren. 2009; 5(4): 176-178

Pharmacotherapy of Alzheimer's disease

doc. MUDr. Roman Jirák CSc
Psychiatrická klinika 1. LF UK a VFN Praha

In this article there are got through contemporary possibilities of pharmacotherapy of Alzheimer´s disease from the evidence-based

medicine point of view. Only 2 approaches are evidence-based at the present time: cholinesterase inhibitors and memantine. There are

hereafter discussed the possibilities of accessory unambiguously non-evidence based medication, possibilities of symptomatic therapy

of behavioural and psychological symptoms of dementia and the possibilities of use of over the counter preparations as the auxiliary

agents of therapy.

Keywords: Alzheimer´s disease, dementia, pharmacotherapy, acetylcholinesterase inhibitors, memantine.

Published: August 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jirák R. Pharmacotherapy of Alzheimer's disease. Praktické lékárenství. 2009;5(4):176-178.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Birks J. Cholinesterase inhibitors for Alzheimer´s disease, Cochrane Database of Systematic Reviews 2006; Issue 1, Art No: CD005593, DOI: 10.1002/14651858. CD005593. Go to original source... Go to PubMed...
    2. Burns A. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol, 2006; 20: 732-755. Go to original source... Go to PubMed...
    3. Caltagirone C, Bianchetti A, Di Luca M, et al. Guidelines for the treatment of Alzheimer´s disease from the Italian Association of Psychogeriatrics. Drugs & Aging 2005; 22(Suppl. 1): 1-26. Go to original source... Go to PubMed...
    4. Jirák R, Borzová C, Konrád J, Franková V, Spousta S. Demence. In: Raboch J, Anders M, Praško J, Hellerová P (eds.). Psychiatrie. Doporučené postupy psychiatrické péče II. Praha: Infopharm, 2006: 22-37.
    5. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastrigmine (review) and memantine for the treatment of Alzheimer´s disease (amended). Includes a review of NICE technology appraisal guidance 19. Issue date: Nov. 2006 (amended Sept. 2007).
    6. Seow D, Gauthier S. Pharmacotherapy of Alzheimer Disease. Can J. Psychiatry 2007; 52: 620-629. Go to original source... Go to PubMed...
    7. Vellas B, Andrieu S, Sampaio C, Wilcock G. Disease-modifying trials in Alzheimer´s disease: a European task force consensus. Lancet Neurol, 2007; 6: 56-62. Go to original source... Go to PubMed...
    8. AD 2000 Collaborative Group: Long-term donepezil treatment in 565 patients with Alzheimer´s disease (AD2000): randomized, double-blind trial. Lancet, 2004; 363(9427): 2105-2115.
    9. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology, 2007; 69(5): 459-468. Go to original source... Go to PubMed...
    10. Mazza M, Capuano A, Bria P, Mazza S. Gingko biloba nad donepezil: a comparison in the treatment of Alzheimer´s dementia in randomized placebo-controlled double-blind study. European Journal of Neurology 2006; 13: 981-985. Go to original source... Go to PubMed...
    11. Volfson C, Moride Y, Perrault A, et al. Review: Donepezil, metrifonate, rivastigmine and Ginkgo biloba are more effective than placebo in Alzheimer´s disease. Evidence-Based Medicine 2001; 6: 14. Go to original source...
    12. Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer´s disease (the SERAD study): a randiomised, placebo-controlled, double-blind trial. The Lancet Neurology, 2009; 8(1): 39-47. Go to original source... Go to PubMed...
    13. Loy C, Schneider L. Galantamine for Alzheimer´s disease and mild cognitive impairment. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD001747.DOI: 10.1002/14651858.CD001747.puib3. Currently published in The Cochrane Database of Systematic Reviews 2009 Issue 1. Go to original source... Go to PubMed...
    14. Rockwood K, Fay S, Song X, et al. Attainment of treatment goals by people with Alzheimer´s disease receiving galantamine: a randomized controlled trial. CMAJ, 2006; 174(8), First published March 22, 2006; doi:10,1503/cmaj.051432. Go to original source... Go to PubMed...
    15. Winblad S, Cummings J, Andreasen N, et al. A six-month double-blind, placebo-controlled study of transdermal patch in Alzheimer´s disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22: 456-467. Go to original source... Go to PubMed...
    16. Winblad S, Grossberg G, Frölich L, et al. IDEAL. A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69(Suppl. 1): S14-SW22. Go to original source... Go to PubMed...
    17. Peskind ER, Potkin SG, Pomara, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24 week randomized controlled trial. Am J Geriatr Psychiatry, 2006; 14(8): 704-715. Go to original source... Go to PubMed...
    18. Waldemar G, Dubois B, et al. Recommendations for the diagnosis and management of Alzheimer´s disease and other disroders associated with dementia: EFNS guideline. Eur J Neurol. 14(1): 1-26.
    19. Napreyenko O, Borzenko I, for the GINDEM-NP Study Group. Ginkgo biloba special extract in dementia with neuropsychiatric features. Arzneimittel Forschung, 2007; 57(1): 4-11. Go to original source...
    20. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer Disease: OmegaAD study. A randomized, double-blind trial. Arch Neurol. 2006; 63(10): 1402-1408. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.